Showing results (291-300 of 434) with videos related to

Sort By:
Pageof 44
Clinical and Experimental Hepatology|September 1, 2017
Severe intrahepatic cholestasis and liver failure after stanozolol usage - case report and review of the literaturePiotr M Stępień, Katarzyna Reczko, Anna Wieczorek, et al.
Clinical and Experimental Hepatology|September 1, 2017
Liver transplantation in Central EuropePavel Trunecka, Zsuzsanna Gerlei, Wojciech Lisik, et al.
Clinical and Experimental Hepatology|September 1, 2017
Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infectionJoanna Pogorzelska, Robert Flisiak
Clinical and Experimental Hepatology|September 1, 2017
Predictors of sustained virological response in patients with hepatitis C virus genotype 3 infectionDorota Zarębska-Michaluk, Dariusz Lebensztejn, Magdalena Chrapek, et al.
Clinical and Experimental Hepatology|September 1, 2017
The occurrence of autoantibodies in patients with chronic HCV infection, including patients dialyzed and after kidney transplantationTadeusz W Łapiński, Magdalena Rogalska-Płońska, Anna Parfieniuk-Kowerda, et al.
Clinical and Experimental Hepatology|September 1, 2017
Surgical treatment of liver tumors - own experience and literature reviewAliaksandr Tarasik, Jerzy Jaroszewicz, Marcin Januszkiewicz
Clinical and Experimental Hepatology|September 1, 2017
Toxic hepatitis caused by the excretions of the Phyllomedusa bicolor frog - a case reportJoanna Pogorzelska, Tadeusz W Łapiński
Clinical and Experimental Hepatology|December 20, 2017
Accelerated hepatocellular carcinoma recurrence rate after postoperative direct-acting antivirals treatment - preliminary reportKarola Warzyszyńska, Maurycy Jonas, Dariusz Wasiak, et al.
Clinical and Experimental Hepatology|December 21, 2017
Normalizing serum hepcidin but not α-1-antitrypsin level during effective treatment of chronic hepatitis CMagdalena Rogalska-Taranta, Jerzy Jaroszewicz, Robert Flisiak
Clinical and Experimental Hepatology|June 16, 2018
Ombitasvir/paritaprevir/ritonavir + dasabuvir + ribavirin in HCV genotype 1 infected patients who failed previous protease inhibitor therapyBéla Hunyady, Margit Abonyi, Zsuzsanna Gerlei, et al.
Pageof 44